C-terminal Hsp90 inhibitors

Patent metadata

Field	Value
Publication number	US-11390640-B2
Application number	US-202017112060-A
Country	US
Kind code	B2
Filing date	Dec 4, 2020
Priority date	Feb 9, 2012
Publication date	Jul 19, 2022
Grant date	Jul 19, 2022

Abstract

Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.

First claim

What is claimed is:

1. A method of treating or preventing a neurodegenerative disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of the formula:

2. The method of claim 1 , wherein the neurodegenerative disorder is sensory neuron glucotoxicity.

3. The method of claim 2 , wherein the sensory neuron glucotoxicity results from hyperglycemia.

4. The method of claim 3 , wherein the hyperglycemia is associated with a diabetic condition.

5. The method of claim 2 , wherein the sensory neuron glucotoxicity results in diabetic peripheral neuropathy.

6. The method of claim 5 , wherein the diabetic peripheral neuropathy is third nerve palsy.

7. The method of claim 5 , wherein the diabetic peripheral neuropathy is mononeuropathy.

8. The method of claim 5 , wherein the diabetic peripheral neuropathy is mononeuropathy multiplex.

9. The method of claim 5 , wherein the diabetic peripheral neuropathy is diabetic amyotrophy.

10. The method of claim 5 , wherein the diabetic peripheral neuropathy is autonomic neuropathy.

11. The method of claim 5 , wherein the diabetic peripheral neuropathy is thoracoabdominal neuropathy.

12. The method of claim 1 , wherein the method comprises treating the neurodegenerative disorder.

13. The method of claim 12 , wherein the method comprises delaying or slowing the progression of the neurodegenerative disorder.

14. The method of claim 12 , wherein the method ameliorates one or more symptoms of the neurodegenerative disorder.

15. The method of claim 1 , wherein the method comprises preventing the neurodegenerative disorder.

16. The method of claim 15 , wherein the method comprises preventing the neurodegenerative disorder in a patient who is at increased risk for the neurodegenerative disorder.

17. The method of claim 15 , wherein the method comprises delaying the onset of the neurodegenerative disorder.

18. The method of claim 15 , wherein the method comprises preventing the individual from developing the neurodegenerative disorder.

19. The method of claim 1 , wherein the therapeutically effective amount is an amount sufficient to inhibit the progression of the disorder.

20. The method of claim 1 , wherein the therapeutically effective amount comprises an amount of the compound sufficient to alleviate one or more symptoms of the disorder.

21. The method of claim 14 , wherein the symptom of the neurodegenerative disorder is pain.

Assignees

• Univ Kansas

Inventors

• Blagg Brian S J
• Kusuma Bhaskar Reddy
• Sundstrom Teather

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07C2601/14

  The ring being saturated · CPC title

• C07H15/207 Primary

  Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins · CPC title

• C07C211/17

  containing only non-condensed rings · CPC title

• C07H15/203 Primary

  Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems · CPC title